Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
1.
Oncogene ; 35(33): 4335-44, 2016 08 18.
Artículo en Inglés | MEDLINE | ID: mdl-26751772

RESUMEN

Hormonal regulation of gene expression by androgen receptor (AR) is tightly controlled by many transcriptional cofactors, including pioneer factors FOXA1 and GATA2, which, however, exhibit distinct expression patterns and functional roles in prostate cancer. Here, we examined how FOXA1, GATA2 and AR crosstalk and regulate hormone-dependent gene expression in prostate cancer cells. Chromatin immunoprecipitation sequencing analysis revealed that FOXA1 reprograms both AR and GATA2 cistrome by preferably recruiting them to FKHD-containing genomic sites. By contrast, GATA2 is unable to shift AR or FOXA1 to GATA motifs. Rather, GATA2 co-occupancy enhances AR and FOXA1 binding to nearby ARE and FKHD sites, respectively. Similarly, AR increases, but not reprograms, GATA2 and FOXA1 cistromes. Concordantly, GATA2 and AR strongly enhance the transcriptional program of each other, whereas FOXA1 regulates GATA2- and AR-mediated gene expression in a context-dependent manner due to its reprogramming effects. Taken together, our data delineated for the first time the distinct mechanisms by which GATA2 and FOXA1 regulate AR cistrome and suggest that FOXA1 acts upstream of GATA2 and AR in determining hormone-dependent gene expression in prostate cancer.


Asunto(s)
Factor de Transcripción GATA2/fisiología , Regulación Neoplásica de la Expresión Génica , Factor Nuclear 3-alfa del Hepatocito/fisiología , Neoplasias de la Próstata/genética , Receptores Androgénicos/fisiología , Línea Celular Tumoral , Humanos , Masculino , Transcripción Genética
2.
Oncogene ; 35(21): 2746-55, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-26364613

RESUMEN

Tamoxifen, an estrogen receptor (ER) antagonist, is the mainstay treatment of breast cancer and the development of resistance represents a major obstacle for a cure. Although long non-coding RNAs such as HOTAIR have been implicated in breast tumorigenesis, their roles in chemotherapy resistance remain largely unknown. In this study, we report that HOTAIR (HOX antisense intergenic RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterparts. Mechanistically, HOTAIR is a direct target of ER-mediated transcriptional repression and is thus restored upon the blockade of ER signaling, either by hormone deprivation or by tamoxifen treatment. Interestingly, this elevated HOTAIR increases ER protein level and thus enhances ER occupancy on the chromatin and potentiates its downstream gene regulation. HOTAIR overexpression is sufficient to activate the ER transcriptional program even under hormone-deprived conditions. Functionally, we found that HOTAIR overexpression increases breast cancer cell proliferation, whereas its depletion significantly impairs cell survival and abolishes tamoxifen-resistant cell growth. In conclusion, the long non-coding RNA HOTAIR is directly repressed by ER and its upregulation promotes ligand-independent ER activities and contributes to tamoxifen resistance.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Antagonistas de Estrógenos/uso terapéutico , ARN Largo no Codificante/metabolismo , Receptores de Estrógenos/metabolismo , Tamoxifeno/farmacología , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Resistencia a Antineoplásicos , Femenino , Humanos , ARN Largo no Codificante/genética , Receptores de Estrógenos/genética , Transducción de Señal/efectos de los fármacos , Activación Transcripcional , Regulación hacia Arriba
3.
Asian Pac J Cancer Prev ; 12(5): 1155-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21875258

RESUMEN

AIM: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. METHODS AND MATERIALS: A retrospective case note review of patients diagnosed with MPM between 1997 and 2007. Overall survival (OS), locoregional recurrence-free survival (LRS) and metastasis-free survival (MFS) were estimated using Kaplan Meier method and comparison were done using log rank test. Multivariate analysis was not done due to the small number of patients. RESULTS: There were 39 patients diagnosed with MPM. Fifty-nine percent of patients presented with Stage III and IV disease. Eight (21%) patients had surgery with 2 patients receiving trimodality treatment and adjuvant chemotherapy respectively. Three patients received adjuvant RT and one patient had no adjuvant therapy. Twelve patients received palliative RT or chemotherapy. Median follow-up was 27.0 weeks. Median overall survival (OS) for all patients was 8.0 months (95% CI 6.3-9.7). One-year and 2-year OS were 25.6% and 6.4% respectively. Thirty-eight patients died of progressive disease and one patient died of other cause. Locoregional recurrences and distant metastases occurred in 3/8 and 5/8 surgically treated patients respectively. Overall, distant metastases occurred in 44% of patients. Surgery did not affect survival outcomes although patients with dual modality treatment showed a trend towards improved survival. Epithelioid tumours had better prognosis (median OS 10.2 months) compared to biphasic (median OS 8.0 months) and sarcomatoid tumours (median OS 1.4 months). CONCLUSION: Future management of MPM will need to emphasize on both locoregional and systemic control and hence, inclusion of patients in clinical trials for multimodality treatment should be encouraged.


Asunto(s)
Mesotelioma/mortalidad , Neoplasias Pleurales/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Quimioterapia Adyuvante , Terapia Combinada , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Mesotelioma/secundario , Mesotelioma/terapia , Persona de Mediana Edad , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Neoplasias Pleurales/patología , Neoplasias Pleurales/terapia , Estudios Retrospectivos , Singapur/epidemiología , Resultado del Tratamiento
4.
Ultrasound Obstet Gynecol ; 38(6): 630-4, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21404357

RESUMEN

OBJECTIVES: To evaluate diagnostic performance of intracranial translucency (IT) for detection of open spina bifida and interobserver agreement for visualization of IT during the 11-13-week scan. METHODS: A retrospective study was undertaken in a tertiary referral center. Two hundred 11-13-week scans for nuchal translucency, performed by sonographers certified by The Fetal Medicine Foundation, U.K., were reviewed independently for IT by two expert observers. When IT was not seen, the observers determined whether this was due to poor IT image quality or the presence of spina bifida. Discordant cases were reviewed by a third observer and the majority decision was used for analysis. All observers were blinded to individual pregnancy outcome and the number of cases with spina bifida. RESULTS: There were 191 normal fetuses, eight fetuses with open spina bifida and one with closed spina bifida (this case was excluded from analysis). IT was seen in 150 fetuses and all were normal. In six of the 49 cases in which IT was not seen, IT non-visibility was attributed to open spina bifida; among these cases, four fetuses had open spina bifida and two were normal. In the remaining 43 cases (including 39 normal fetuses), IT non-visibility was attributed to inadequate image quality. Sensitivity was 50% (4/8) and specificity was 99% (150/152). Concordance between the two observers concerning IT visibility was 79%, (κ = 0.47, representing moderate agreement). CONCLUSION: There was moderate interobserver agreement for visualization of IT on images obtained for nuchal translucency measurement at 11-13 weeks. When IT was confidently seen, open spina bifida could be excluded. However, non-visibility of IT correctly diagnosed only 50% of fetuses with open spina bifida.


Asunto(s)
Cuarto Ventrículo/diagnóstico por imagen , Medida de Translucencia Nucal/métodos , Espina Bífida Quística/diagnóstico por imagen , Adulto , Largo Cráneo-Cadera , Femenino , Cuarto Ventrículo/anomalías , Cuarto Ventrículo/embriología , Humanos , Persona de Mediana Edad , Variaciones Dependientes del Observador , Valor Predictivo de las Pruebas , Embarazo , Primer Trimestre del Embarazo , Estudios Retrospectivos , Espina Bífida Quística/embriología , Adulto Joven
5.
Laryngoscope ; 116(7): 1258-62, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16826071

RESUMEN

OBJECTIVES: Radiotherapy to head and neck tumors can potentially damage the auditory pathways. This has relevance in cochlear implants and there is a need for clinical studies to confirm the feasibility of cochlear implantation in these patients. METHODS: The records of all patients who had received cochlear implants at our institution were reviewed in this retrospective study and those who had prior irradiation for head and neck tumors were further studied. Case controls consisted of comparable cochlear implant recipients who did not have prior radiotherapy. RESULTS: Four of 230 patients met the criteria for further study. They had received radiotherapy for nasopharyngeal carcinoma 11 to 28 years ago and the postimplant follow-up period ranged from 9 to 46 months. The implanted ear of each patient had favorable preoperative promontory stimulation results. Postimplant, all patients were satisfied with their hearing outcomes and the improvement in speech discrimination scores was comparable to the controls. These cases also illustrated specific clinical concerns, including 1) radiation-induced endocrine dysfunction was common and, if overlooked, could result in increased anesthetic risks, and 2) irreversible eustachian tube dysfunction led to chronic middle ear problems, which complicated surgery; the use of modified surgical techniques overcame these difficulties. CONCLUSIONS: Deafened postirradiated patients with nasopharyngeal carcinoma were able to achieve good postimplant hearing outcomes comparable to those of nonirradiated patients. Should cochlear implantation be indicated in patients who have had prior radiation to the head and neck, specific preoperative, intraoperative, and postoperative issues have to be addressed.


Asunto(s)
Carcinoma/radioterapia , Cóclea/efectos de la radiación , Implantación Coclear/métodos , Sordera/cirugía , Neoplasias Nasofaríngeas/radioterapia , Traumatismos por Radiación/complicaciones , Anciano , Carcinoma/patología , Cóclea/cirugía , Sordera/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Nasofaríngeas/patología , Estudios Retrospectivos
6.
Laryngoscope ; 115(10): 1823-6, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16222203

RESUMEN

OBJECTIVES: The cochlea may be damaged by modern conventional radiotherapy (RT) for head and neck cancers when the ear is included in the radiation field. It is unclear however, if the retro-cochlear auditory pathways are affected as well, which has clinical significance in cochlear implantation. This study aims to investigate the integrity of the retro-cochlear auditory pathways in patients who had received RT for nasopharyngeal carcinoma. STUDY DESIGN: Prospective study. METHODS: Patients who were newly diagnosed with nasopharyngeal carcinoma and treated by RT alone were studied. Evoked response audiometry and PTAs were carried out prior to and after RT (at 3, 18, and 48 months postRT). In addition, evoked response audiometry was also performed during the 3rd, 5th, and 7th week of RT. Waves 1 to 5, 1 to 3, and 3 to 5 latencies were measured. The values recorded during and postRT were compared with those recorded before RT. In addition, a subset of ears that demonstrated postRT sensorineural hearing loss were identified so that their respective wave 1 to 5 interwave latencies could be similarly compared. Wilcoxon signed ranks test was used in the statistical analysis. To confirm that the cochlea and internal auditory meatus receive significant doses of radiation, the RT treatment plans of nine other nasopharyngeal carcinoma patients treated by the same RT technique were analyzed to derive dose-volume histograms of these structures. RESULTS: Twenty-seven patients (20 males and 7 females) with a mean age of 51.2 (range 36-75) years participated in the study. There was no statistically significant difference in waves 1 to 5, 1 to 3, and 3 to 5 interwave latencies recorded during RT and postRT as compared with those recorded before RT (P > .05). Pre- and postRT wave 1 to 5 latencies of the 16 ears that had postRT hearing deterioration were also not statistically significant (P = .366). The mean radiation doses delivered to the cochlea and internal auditory meatus ranged from 24.1 to 62.2 Gy and 14.4 to 43.4 Gy, respectively. CONCLUSION: This study suggests in patients who have had RT for nasopharyngeal carcinoma, the retro-cochlear auditory pathways are functionally intact even in the longer term.


Asunto(s)
Vías Auditivas/efectos de la radiación , Pérdida Auditiva Sensorineural/etiología , Neoplasias Nasofaríngeas/radioterapia , Traumatismos por Radiación/diagnóstico , Radioterapia/efectos adversos , Adulto , Anciano , Audiometría de Respuesta Evocada , Nervio Coclear/efectos de la radiación , Femenino , Pruebas Auditivas , Humanos , Masculino , Persona de Mediana Edad , Traumatismos por Radiación/etiología
7.
Br J Cancer ; 93(3): 279-86, 2005 Aug 08.
Artículo en Inglés | MEDLINE | ID: mdl-16012523

RESUMEN

We compared concurrent combination chemotherapy and radiotherapy with surgery and adjuvant radiotherapy in patients with stage III/IV nonmetastatic squamous cell head and neck cancer. Patients with non-nasopharyngeal and nonsalivary resectable squamous cell head and neck cancer were randomised to receive either surgery followed by adjuvant radiotherapy (60 Gy over 30 fractions) or concurrent combination chemotherapy and radiotherapy (66 Gy in 33 fractions). Combination chemotherapy comprised two cycles of i.v. cisplatin 20 mg m(-2) day(-1) and i.v. 5-fluorouracil 1000 mg m(-2) day(-1), both to run over 96 h given on days 1 and 28 of the radiotherapy. A total of 119 patients were randomised. At a median follow-up of 6 years, there was no significant difference in the 3-year disease-free survival rate between the surgery and concurrent chemoradiotherapy (50 vs 40% respectively). The overall organ preservation rate or avoidance of surgery to primary site was 45%. Those with laryngeal/hypopharyngeal disease subsite had a higher organ-preservation rate than the rest (68 vs 30%). Combination chemotherapy and concurrent irradiation with salvage surgery was not superior to conventional surgery and postoperative radiotherapy for resectable advanced squamous cell head and neck cancer. However, this form of treatment schedule with a view to organ-preservation can be attempted especially for those with laryngeal/hypopharyngeal and possibly oropharyngeal disease subsites.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/terapia , Neoplasias de Cabeza y Cuello/terapia , Procedimientos Quirúrgicos Otorrinolaringológicos , Radioterapia Adyuvante , Adulto , Anciano , Carcinoma de Células Escamosas/mortalidad , Cisplatino/uso terapéutico , Terapia Combinada , Femenino , Fluorouracilo/uso terapéutico , Neoplasias de Cabeza y Cuello/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
8.
Ultrasound Obstet Gynecol ; 24(7): 706-15, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15586358

RESUMEN

OBJECTIVES: To evaluate the time of appearance and pattern of development of fetal cerebral sulci at prenatal ultrasound. METHODS: We studied 50 normal fetuses for visibility of cerebral sulci, especially sulci which appear early in anatomical studies, namely the parieto-occipital fissure, calcarine sulcus, cingulate sulcus, convexity sulci and insula/Sylvian fissure. The gestational ages of the fetuses studied ranged from 15.6 to 29.6 weeks. RESULTS: Sulci could be seen by transabdominal ultrasound as early as 18.5 weeks. Medial hemispheric sulci and the insula were visible earlier and more confidently than convexity sulci. The earliest gestational ages at which specific sulci could be seen in any fetus were as follows: parieto-occipital fissure 18.5 weeks, calcarine sulcus 18.5 weeks, cingulate sulcus 23.2 weeks and convexity sulci 23.2 weeks. In the present series, the gestational ages at which these sulci were always visible were as follows: parieto-occipital fissure >20.5 weeks, calcarine sulcus >21.9 weeks, cingulate sulcus >24.3 weeks and convexity sulci >27.9 weeks. The insula and its margin (the circular sulcus) and the overgrowing opercula undergo characteristic maturation. The circular sulcus at the margin of the insula was initially smooth but started becoming angular after about 17 weeks as it started to be overgrown by the parietal and temporal lobe opercula. Initially the insula/operculum angle was obtuse. An acute angle was first evident at 23.2 weeks and in all fetuses older than 24.5 weeks. Our ultrasound data were consistent with anatomical studies and fetal magnetic resonance imaging findings. CONCLUSIONS: Some cerebral sulci can be seen at prenatal ultrasound as early as 18.5 weeks. Familiarity with the normal pattern of sulcal development and the discriminating gestational ages for the appearance of different sulci may allow early suspicion of lissencephaly.


Asunto(s)
Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/embriología , Desarrollo Fetal/fisiología , Ultrasonografía Prenatal/métodos , Femenino , Edad Gestacional , Humanos , Embarazo , Segundo Trimestre del Embarazo
9.
Ultrasound Obstet Gynecol ; 24(7): 716-23, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15586369

RESUMEN

OBJECTIVE: To report on the prenatal ultrasound findings in fetuses with lissencephaly associated with Miller-Dieker syndrome (MDS) and to compare these findings with those of magnetic resonance imaging (MRI). METHODS: Cases of MDS confirmed by postnatal chromosome microdeletion analysis were identified through review of patient records. Prenatal ultrasound scans were reviewed retrospectively by two radiologists. For cerebral cortical development, the Sylvian, parieto-occipital and calcarine fissures, and the cingulate sulcus and sulci over the cerebral convexity were evaluated. If one or more of these fissures or sulci were not visualized at the expected gestational age or their appearance was abnormal for gestational age, cortical development was considered delayed. Prenatal and postnatal MRI examinations were reviewed by a pediatric neuroradiologist. RESULTS: There were seven cases of MDS. In three cases, the prenatal diagnosis of agyria/lissencephaly was prospectively suspected by ultrasound at 23, 26 and 30 weeks, and subsequently confirmed by prenatal MRI. When we retrospectively reviewed the prenatal ultrasound scans of all fetuses, all had delayed cortical development identified on ultrasound performed after 23 weeks' gestation. In all cases the Sylvian fissure was abnormal on both ultrasound and MRI. In one fetus, a normal cortical appearance for gestational age was seen at the initial 20-week ultrasound examination, but delayed cortical development was identified at a 24-week scan. Mild ventriculomegaly was seen in six fetuses and dysgenesis of the corpus callosum in one. Extracranial abnormalities were detected in five fetuses. Delayed cortical development was seen in two fetuses with mild ventriculomegaly, but no other fetal anomalies. CONCLUSIONS: In fetuses with MDS, delayed cortical development can be suspected on ultrasound as early as 23 weeks' gestation. This finding warrants further investigations including MRI and FISH analysis for chromosome 17p13.3 deletion.


Asunto(s)
Corteza Cerebral/diagnóstico por imagen , Anomalías Congénitas/diagnóstico por imagen , Ultrasonografía Prenatal , Corteza Cerebral/embriología , Deleción Cromosómica , Anomalías Congénitas/diagnóstico , Anomalías Congénitas/genética , Femenino , Humanos , Hibridación Fluorescente in Situ , Imagen por Resonancia Magnética , Embarazo , Diagnóstico Prenatal , Estudios Retrospectivos , Síndrome
10.
Eur J Cancer ; 39(11): 1535-41, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12855259

RESUMEN

The survival outcome of patients with systemic cancer differs significantly between individuals even within the same tumour type. We set out to illustrate this by analysing the factors determining survival in patients with metastatic disease from nasopharyngeal carcinoma (NPC) and to design a scoring system based on these prognostic factors. Patients referred between January 1994 and December 1999 were retrospectively analysed. Factors analysed included patient (age group, gender, performance status (BS) at diagnosis of metastases), disease (number of metastatic sites, specific metastatic sites, disease-free interval (DFI), metastases at presentation, presence of locoregional recurrence), and laboratory factors (leucocyte count, haemoglobin level, albumin level). Univariate and multivariable analyses were performed using the Cox proportion hazards model. A numerical score was derived from the regression coefficients of each independent prognostic variable. The prognostic index score (PIS) of each patient was calculated by totalling up the scores of each independent variable. Independently significant, negative prognostic factors were liver metastasis, lung metastasis, anaemia, poor PS, distant metastasis at initial diagnosis, and a DFI of <6 months. Three prognostic groups based on the PIS were obtained: (i) good risk (PIS=0-6); (ii) intermediate risk (7-10); (iii) poor risk (>or=11). The median survivals for these groups were 19.5, 10, and 5.8, months, respectively, (log rank test: P<0.0001). The variable prognosis of patients with disseminated NPC can be assessed by using easily available clinical information (patient, disease and laboratory factors). The PIS system will need to be validated on prospectively collected data of another cohort of patients.


Asunto(s)
Neoplasias Nasofaríngeas/mortalidad , Adulto , Anciano , Antineoplásicos/uso terapéutico , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Neoplasias Nasofaríngeas/tratamiento farmacológico , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Cuidados Paliativos , Pronóstico , Análisis de Regresión , Análisis de Supervivencia
11.
Ann Oncol ; 13(1): 150-6, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11865813

RESUMEN

BACKGROUND: We conducted two parallel phase II trials in chemonaïve and previously treated patients with metastatic nasopharyngeal carcinoma (NPC) to evaluate the tumour response, progression-free and overall survival, and toxicity of gemcitabine. PATIENTS AND METHODS: Gemcitabine 1250 mg/m2 was given on days 1 and 8 of a 21-day cycle. Patients with an Eastern Cooperative Oncology Group performance status <2, adequate renal, hepatic and bone marrow function, and radiologically measurable NPC were eligible. RESULTS: Twenty-five chemonaïve and 27 previously treated patients were enrolled. The overall response rate was 28% [95% confidence interval (CI) 14% to 48%] for the chemonaïve and 48% (95% CI 31% to 66%) for previously treated patients. Toxicities greater than or equal to grade 3 occurred in 15 (60%) chemonaïve and 13 (48%) previously treated patients. Neutropenia was uncommon in chemonaïve patients, but occurred in 37% of previously treated patients. The median time to progression was 3.6 months (range 0.9-7.9) for chemonaïve and 5.1 months (0.9-13.1) for previously treated patients. Median overall survival time was 7.2 months (1.4-15.6) and 10.5 months (2.4-15.0) for chemonaïve and previously treated patients, respectively. CONCLUSIONS: Gemcitabine has moderate activity in NPC with minimal toxicity, and is also an effective salvage agent for patients who have failed or progressed after treatment with other agents.


Asunto(s)
Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapéutico , Neoplasias Nasofaríngeas/tratamiento farmacológico , Neoplasias Nasofaríngeas/patología , Metástasis de la Neoplasia/tratamiento farmacológico , Adulto , Anciano , Desoxicitidina/administración & dosificación , Desoxicitidina/efectos adversos , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tasa de Supervivencia , Factores de Tiempo , Gemcitabina
13.
Am J Otol ; 21(6): 871-6, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11078078

RESUMEN

OBJECTIVE: This article describes a series of patients with nasopharyngeal carcinoma involvement of the cerebellopontine angle and discusses the clinical significance of this entity. SETTING: Tertiary referral center. STUDY DESIGN: Retrospective case study. PATIENTS: Patients who were diagnosed with nasopharyngeal carcinoma with clinical features of cerebellopontine involvement by tumor. INTERVENTIONS: Cerebellopontine involvement by tumor confirmed by computed tomography, magnetic resonance imaging, or both. RESULTS: Patients with this entity either had advanced disease or had been treated previously for advanced nasopharyngeal carcinoma. They had varied clinical features attributable to cerebellopontine involvement, such as sensorineural deafness, dizziness, facial palsy, and facial numbness. CONCLUSIONS: Cerebellopontine angle involvement by nasopharyngeal carcinoma is a difficult entity, both from the diagnostic and therapeutic points of view. In high-risk patients, particularly in patients who were previously treated for advanced nasopharyngeal carcinoma, a high index of suspicion for nasopharyngeal carcinoma involvement of the cerebellopontine angle is warranted when they experience unexplained neurootologic symptoms such as sensorineural hearing loss, dizziness and facial palsy.


Asunto(s)
Carcinoma/complicaciones , Carcinoma/patología , Neoplasias Cerebelosas/diagnóstico , Ángulo Pontocerebeloso/diagnóstico por imagen , Ángulo Pontocerebeloso/patología , Neoplasias Nasofaríngeas/diagnóstico , Adulto , Neoplasias Cerebelosas/complicaciones , Neoplasias Cerebelosas/radioterapia , Diagnóstico Diferencial , Femenino , Pérdida Auditiva Sensorineural/diagnóstico , Pérdida Auditiva Sensorineural/etiología , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Neoplasias Nasofaríngeas/complicaciones , Neoplasias Nasofaríngeas/radioterapia , Invasividad Neoplásica , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X
14.
Otolaryngol Head Neck Surg ; 123(4): 505-7, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11020195

RESUMEN

Although Epstein-Barr virus (EBV) IgA serology has been established as an effective marker for nasopharyngeal carcinoma (NPC), it remains unclear how useful or cost-effective it is as a screening test. This article is aimed at establishing how these tests could be used most effectively in the diagnosis of NPC in an otolaryngology outpatient clinic. A total of 111 consecutive patients with NPC and an equal number of control subjects were studied. Forty-seven patients with NPC had early (AJCC stages 1 and 2) and 64 had advanced (stages 3 and 4) disease. A positive early antigen (EA) serology result was found in 81.2% of NPC patients and in none of the controls. Negative EA and viral capsid antigen (VCA) serology results were present in 2.7% of NPC patients and in 46.8% of controls. Negative EA and positive VCA serology results were found in 30.0% of NPC patients with early disease, 7.8% of NPC patients with advanced disease, and 53.2% of controls. Given its high specificity, serology for EA is recommended as a clinically useful screening test. Serology for VCA, although highly sensitive, has an unacceptably high false-positive rate, and its cost-effectiveness as a universal screening test is questionable.


Asunto(s)
Adenocarcinoma/diagnóstico , Adenocarcinoma/virología , Infecciones por Virus de Epstein-Barr/diagnóstico , Herpesvirus Humano 4/aislamiento & purificación , Neoplasias Nasofaríngeas/diagnóstico , Neoplasias Nasofaríngeas/virología , Adulto , Anciano , Biomarcadores/análisis , Infecciones por Virus de Epstein-Barr/epidemiología , Antígenos Nucleares del Virus de Epstein-Barr/análisis , Femenino , Humanos , Masculino , Tamizaje Masivo/métodos , Persona de Mediana Edad , Sensibilidad y Especificidad , Pruebas Serológicas
16.
J Laryngol Otol ; 113(7): 633-6, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10605559

RESUMEN

Nasopharyngeal carcinoma (NPC) can be difficult to diagnose. Not only is the post-nasal space (PNS) inaccessible to examination, it is frequently occupied by normal lympho-epithelium which can make differentiation from NPC difficult. Together with its frequent atypical presentation, it is not surprising that the diagnosis is missed or delayed. This is undesirable as the treatment of early NPC carries an excellent prognosis. The aim of this study is to ascertain the extent of the problem of missed or delayed diagnosis and to study the factors responsible. This was a retrospective study of all newly diagnosed patients with NPC from the Singapore General Hospital and treated in the Department of Therapeutic Radiology in the year 1996 (1 January-31 December). A total of 126 patients were studied. Eighteen patients (14.3 per cent) were found to have delayed diagnosis of more than a month. The delay ranged from 1.2 to 25 months (mean 7.2 months). Factors identified which contributed to delayed diagnosis included i) Clinicians not considering a diagnosis of NPC ii) Clinicians suspecting NPC but misled by the results of investigations iii) Patients refusing investigation or defaulting follow-up. Nearly a fifth of patients with NPC had delayed diagnosis. Many of the factors responsible for the delays appear to be preventable by better patient education and counselling, doctors having sharper clinical acumen and skills in NPC diagnosis and the hospital administration having a system of tracking down high risk patients who default.


Asunto(s)
Neoplasias Nasofaríngeas/diagnóstico , Competencia Clínica , Humanos , Pacientes Desistentes del Tratamiento , Educación del Paciente como Asunto , Factores de Tiempo
17.
Radiology ; 213(3): 681-9, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10580939

RESUMEN

PURPOSE: To determine and compare the diagnostic performance of fetal middle cerebral (MCA), renal (RA), and umbilical (UA) arterial Doppler ultrasonography (US) for prediction of adverse perinatal outcome in suspected intrauterine growth restriction (IUGR). MATERIALS AND METHODS: Two hundred ninety-three small-for-gestational age fetuses (24-39 weeks at recruitment and US-estimated weight or abdominal circumference below 10th percentile) were prospectively examined with Doppler US of the UA, MCA, and RA. Clinicians were blinded to MCA and RA Doppler measurements. RESULTS: Seventy-six fetuses (25.9%) had at least one major or minor adverse perinatal outcome. Major outcomes included stillbirth, neonatal death, neurologic complication, and necrotizing enterocolitis. The MCA pulsatility index (PI), compared with the UA PI and RA PI, was more sensitive (72.4% vs 44.7% and 8.3%) but less specific (58.1% vs 86.6% and 92.6%) in predicting adverse outcome. The UA PI had the highest positive likelihood ratio (ratio, 3.3); the MCA PI had the lowest negative likelihood ratio (ratio, 0.48). When gestational age at the first Doppler US examination was less than 32 weeks, the MCA PI had a sensitivity of 95.5% and negative predictive value of 97.7% for major adverse outcome (negative likelihood ratio, 0.10). CONCLUSION: In suspected IUGR, while an abnormal UA PI is a better predictor of adverse perinatal outcome than an abnormal MCA or RA PI, a normal MCA PI may help to identify fetuses without major adverse perinatal outcome, especially before 32 weeks gestational age.


Asunto(s)
Retardo del Crecimiento Fetal/diagnóstico por imagen , Feto/irrigación sanguínea , Ultrasonografía Doppler , Ultrasonografía Prenatal , Encéfalo/irrigación sanguínea , Encéfalo/embriología , Femenino , Edad Gestacional , Humanos , Recién Nacido , Riñón/irrigación sanguínea , Riñón/embriología , Masculino , Valor Predictivo de las Pruebas , Embarazo , Pronóstico , Estudios Prospectivos , Flujo Pulsátil/fisiología , Radiografía , Arterias Umbilicales/diagnóstico por imagen
18.
Ann Acad Med Singap ; 28(4): 525-8, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10561766

RESUMEN

The result with radiotherapy alone in patients with locally advanced nasopharyngeal carcinoma (NPC) was disappointing. Encouraging results have been reported with the use of concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Hence, we decided to explore the use of this treatment schedule in patients who presented with locally advanced disease (UICC/AJCC classification system). Between July 1995 and March 1996, 14 patients with locally advanced NPC were treated with the following schedule: radiation therapy was given conventionally to a total of 66 to 70 Gy to both the nasopharynx and neck with or without parapharyngeal/intracavitary boost; chemotherapy consisted of intravenous cisplatin at 20 mg/m2/day and intravenous 5-flurouracil 1000 mg/m2/day, infused over 8 hours on days 1 to 4 during the first and fifth week of radiation therapy. Depending on the patient's tolerability and clinical assessment of toxicity, a third cycle of chemotherapy was planned 4 to 5 weeks after the second cycle, upon the completion of the radiotherapy. Twelve patients completed all intended treatment. Two patients failed to do so due to treatment-related mortality. The median follow-up duration was 30 months. Limiting toxicities were myelosuppression and oropharyngeal mucositis. The overall response rate was a 100% at both the primary and nodal sites of disease. The median disease-free survival was 21 months. Forty per cent of the patients were alive at 3 years. This treatment schedule was associated with an unacceptable treatment-related death rate. As a result, this protocol was terminated.


Asunto(s)
Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/radioterapia , Neoplasias Nasofaríngeas/tratamiento farmacológico , Neoplasias Nasofaríngeas/radioterapia , Adulto , Anciano , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/efectos adversos , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/mortalidad , Cisplatino/administración & dosificación , Cisplatino/efectos adversos , Terapia Combinada , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/efectos adversos , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Nasofaríngeas/mortalidad , Radioterapia/efectos adversos , Dosificación Radioterapéutica , Factores de Tiempo
19.
Cancer ; 86(10): 1912-20, 1999 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-10570413

RESUMEN

BACKGROUND: The objective of the current study was to describe the survival of nasopharyngeal carcinoma (NPC) patients in Singapore, verify the prognostic value of the revised 1997 TNM staging system, and develop a multivariate prognostic model for NPC. In addition, the authors also examined the prognostic value of characteristics of lymph node spread and parapharyngeal involvement. METHODS: A prospectively maintained database containing clinical and computed tomography scan data was used to reclassify 677 NPC patients treated between 1992 and 1994 according to the new staging system. Records were linked with the death registry to ascertain the patient's vital status and date of death. Overall and stage specific survival were analyzed using the Kaplan-Meier method and the log rank test. Univariate and multivariate Cox proportional hazards regression analysis were used to obtain prognostic models. RESULTS: Two hundred seventy-four deaths (40.5%) occurred. The 5-year survival rate was 56.6% (95% confidence interval [95% CI], 52.3%, 60.7%). The stage specific 5-year survival rates were: Stage I, 88%; Stage IIA, 75%; Stage IIB, 74%; Stage III, 60%; Stage IVA, 35%; and Stage IVB, 28%. TNM stage was found to be a statistically significant prognostic factor (P < 0.0001). Cranial nerve (hazard ratio [HR]: 2.77), orbit (HR: 5.71), and intracranial involvement (HR: 2.46) conferred a particularly bad prognosis in univariate analysis. Independently significant prognostic factors were age; lymph node status; and paraoropharyngeal, cranial nerve, orbit, and nasal involvement. Among lymph node positive patients, independently significant prognostic lymph node characteristics were Ho level and laterality. Although parapharyngeal involvement appeared to be prognostically unimportant, paraoropharyngeal involvement distinguished a subgroup with a poorer prognosis (HR: 1.84; 95% CI, 1.45, 2.34; P < 0.0001). Lateral spread to the medial infratemporal fossa and beyond also was found to confer a poorer prognosis. CONCLUSIONS: The results of the current study show that the revised 1997 TNM staging system is prognostically useful. Subdivision into paraoropharyngeal involvement and using the medial infratemporal fossa to delineate prognostically significant lateral spread should be considered in future revisions.


Asunto(s)
Neoplasias Nasofaríngeas/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Metástasis Linfática , Persona de Mediana Edad , Análisis Multivariante , Invasividad Neoplásica , Estadificación de Neoplasias , Pronóstico , Modelos de Riesgos Proporcionales , Singapur , Tomografía Computarizada por Rayos X
20.
Int J Radiat Oncol Biol Phys ; 45(3): 597-601, 1999 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-10524411

RESUMEN

PURPOSE: Nasopharyngeal carcinoma (NPC) is endemic in Singapore. Nearly 60% of the patients diagnosed with NPC will present with locally advanced disease. The North American Intergroup study 0099 reported improved survival outcome in patients with locally advanced NPC who received combined chemoradiotherapy when compared to radiotherapy alone. Hence we explored the feasibility and efficacy of a similar protocol in our patients. METHODS AND MATERIALS: Between June 1996 and December 1997, 57 patients were treated with the following schedule as described. Radical radiotherapy (RT) of 66-70 Gy to the primary and neck with cisplatin (CDDP) 25 mg/m2 on days 1-4 given by infusion over 6-8 hours daily on weeks 1, 4, and 7 of the RT. This is followed by a further 3 cycles of adjuvant chemotherapy starting from week 11 from the first dose of radiation (CDDP 20 mg/m2/d and 5-fluorouracil [5-FU] 1 gm/m2/d on days 1-4 every 28 days). RESULTS: The majority of patients (68%) had Stage IV disease. About 54% of patients received all the intended treatment; 75% received all 3 cycles of CDDP during the RT phase and 63% received all three cycles of adjuvant chemotherapy. The received dose intensity of CDDP and 5-FU of greater than 0.8 was achieved in 58% and 60% of the patients respectively. Two treatment-related deaths due to reactivation of hepatitis B and neutropenic sepsis respectively, were encountered. At median follow-up of 16 months, 14 patients had relapsed, 12 systemically and 2 loco-regionally. CONCLUSION: Due to the acceptable tolerability of such a protocol in our cohort of patients, we have embarked on a Phase III study to confirm the results of the 0099 Intergroup study in the Asian context.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Nasofaríngeas/tratamiento farmacológico , Neoplasias Nasofaríngeas/radioterapia , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Quimioterapia Adyuvante , Cisplatino/administración & dosificación , Cisplatino/efectos adversos , Terapia Combinada , Estudios de Factibilidad , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/efectos adversos , Estudios de Seguimiento , Humanos , Riñón/efectos de los fármacos , Riñón/efectos de la radiación , Masculino , Persona de Mediana Edad , Neutropenia/etiología , Dosificación Radioterapéutica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...